Navigation Links
Bunge Reports Fourth Quarter Net Income of $245 Million
Date:2/7/2008

(18) (27)

Other 95 -

Cash provided by financing activities 1,818 891

Effect of exchange rate changes on cash

and cash equivalents 59 20

Net increase in cash and cash equivalents 616 11

Cash and cash equivalents, beginning of period 365 354

Cash and cash equivalents, end of period $981 $365

Reconciliation of Non-GAAP Measures

This earnings release contains total segment operating profit, net financial debt and net financial debt less readily marketable inventories, which are "non-GAAP financial measures" as this term is defined in Regulation G of the Securities Exchange Act of 1934. In accordance with Regulation G, Bunge has reconciled these non-GAAP financial measures to the most directly comparable U.S. GAAP measures.

Total Segment Operating Profit

Total segment operating profit, which is the consolidated segment operating profit of all of Bunge's operating segments, is Bunge's consolidated income from operations before income tax that includes interest income of each segment and an allocated portion of the foreign exchange gains and losses and of interest expense relating to debt financing operating working capital, including readily marketable inventories.

Total segment operating profit is a non-GAAP financial measure and is not intended to replace income from operations before income tax, the most directly comparable GAAP financial measure. Total segment operating profit is a key performance measurement used by Bunge's management to evaluate whether operating activities cover the financing costs of its business. Bunge believes total segment operating profit is a more complete measure of its operating profitability, since it allocates foreign exchange gains and losses and the cost of deb
'/>"/>

SOURCE Bunge Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Recent Research Reports and Near-Term Corporate Events
5. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
6. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
7. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
8. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
9. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
10. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
11. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
(Date:5/17/2013)... International, Inc. (NASDAQ: YONG ) ("Yongye" or ... crop nutrient products in the People,s Republic ... 16, 2013, the special committee (the "Special Committee") of ... provided a letter (the "Letter") issued by Abax Global ... to Full Alliance International Limited ("Full Alliance"). The Letter, ...
(Date:5/17/2013)... 17, 2013 The paradigm of ‘one ... systems that can help predict the adverse and therapeutic ... Stepaniants, Head of Computational Biology at the Genomics Laboratory, ... to ensure high-quality genomics when used as part of ... to complex data sets to identify key clinical targets ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... Milestones, CRANBURY, N.J., Nov. 3 Amicus Therapeutics,(Nasdaq: ... third quarter of,2008. On a reported basis calculated in ... a net loss,attributable to common stockholders of $0.36 per ... three months ended September 30, 2008. As of,September 30, ...
... Nov. 3 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... announced today that BUYINS.NET, http://www.buyins.net, is initiating ... data to October 2008. From November 2006 to ... BMOD have traded,for a total dollar value of ...
... and GUELPH, Ontario, Nov. 3 LI-COR,Biosciences ... agreement to,distribute LI-COR biotechnology products in Canada ... local presence of Mandel Scientific skilled staff, ... enhance our ability to serve,our Canadian customers," ...
Cached Biology Technology:Amicus Therapeutics Announces Third Quarter 2008 Financial Results 2Amicus Therapeutics Announces Third Quarter 2008 Financial Results 3Amicus Therapeutics Announces Third Quarter 2008 Financial Results 4Amicus Therapeutics Announces Third Quarter 2008 Financial Results 5Amicus Therapeutics Announces Third Quarter 2008 Financial Results 6Amicus Therapeutics Announces Third Quarter 2008 Financial Results 7Amicus Therapeutics Announces Third Quarter 2008 Financial Results 8Amicus Therapeutics Announces Third Quarter 2008 Financial Results 9Amicus Therapeutics Announces Third Quarter 2008 Financial Results 10Amicus Therapeutics Announces Third Quarter 2008 Financial Results 11Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 2Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 3Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 4LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement 2
(Date:5/17/2013)... The AGA Research Foundation announced a new grant ... the gut microbiota, one of today,s most exciting areas ... The AGA Research Awards Panel selected Andrew T. Chan, ... and Harvard Medical School, Boston, as the 2013 AGA-Elsevier ... receive $25,000 of funding, commencing in July 2013, to ...
(Date:5/17/2013)... May 17, 2013, Shenzhen, China---- Why Tibetan antelope ... Qinghai-Tibetan Plateau? In a collaborative research published in ... BGI, and other institutes provide evidence that some ... adaption to harsh highland environments. The data in ... specific genetic mechanisms and the biology of other ...
(Date:5/16/2013)... a commitment to the support of underrepresented minority ... Foundation has announced the inaugural AGA Investing in ... by the National Institute of Diabetes and Digestive ... underrepresented minority students to further their research careers ... establishing this new award, AGA demonstrates its commitment ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... at Schepens Eye Research Institute, an affiliate of Harvard ... inside blood vessel cells that controls angiogenesis (new blood ... and off by the balance between two enzymes (known ... of the same lipid membrane to fulfill opposite missions, ...
... Institutes of Health today provided the clearest picture yet of ... genes associated with an increased risk of breast cancer. The ... 2 (BRCA2). In addition, the study identified key predictors for ... mutations. , Each year, approximately 200,000 women in the ...
... a Saint Louis University vaccine researcher scrutinizes what in ... available anthrax vaccine. , This new type of anthrax ... according to peer-reviewed research published in Vaccine . ... given to 100 volunteers at four sites around the ...
Cached Biology News:Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 2Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 3New findings offer more complete view of breast cancer gene mutations in US population 2New findings offer more complete view of breast cancer gene mutations in US population 3
... Thermo's orbital shaker stands ... a more ergonomic height, and ... Purpose-built from welded tubular steel, ... to support the weight and ...
... 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat inactivation ... Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM KCl, ... BSA, 50% glycerol. Shipping and Storage: Shipped on ... unit is defined as the amount of enzyme ...
... experiment based analysis package designed with easy ... and powerful functionality., Image acquisition interface is ... easy image capture. Sequential and dynamic ... Saturation Warning Single ...
... stainless-steel shaker flask clips, purpose-designed to firmly ... All clips are equipped with a top ... include a bottom retainer spring, and silicon ... expensive glassware. Clips include the required ...
Biology Products: